Q3-24 revenues of $12.6 million , down 11% from Q3-23, excluding XIIDRA, growth trend from continued business remains healthy at +9%, Q3-24 vs Q3-23 Q3-24 adjusted EBITDA loss of $1.5 million compared to $2.5 million for Q3-23, down 40% MONTREAL , Sept. 12, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, today reported its financial results for the... Read More